Axxcess Wealth Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.68M Buy
10,748
+1,433
+15% +$215K 0.03% 420
2026
Q1
$1.42M Sell
9,315
-242
-3% -$37.1K 0.05% 210
2025
Q4
$1.32M Buy
9,557
+1,626
+21% +$213K 0.02% 460
2025
Q3
$1.02M Buy
7,931
+3,002
+61% +$366K 0.02% 441
2025
Q2
$596K Sell
4,929
-279
-5% -$31.4K 0.01% 548
2025
Q1
$581K Sell
5,208
-1,875
-26% -$200K 0.02% 513
2024
Q4
$689K Buy
7,083
+4,267
+152% +$455K 0.02% 481
2024
Q3
$324K Sell
2,816
-17
-0.6% -$1.93K 0.01% 670
2024
Q2
$302K Buy
2,833
+21
+0.7% +$2.11K 0.01% 646
2024
Q1
$272K Buy
2,812
+20
+0.7% +$2.05K 0.01% 699
2023
Q4
$282K Buy
2,792
+512
+22% +$49.4K 0.01% 663
2023
Q3
$232K Buy
2,280
+280
+14% +$28.4K 0.01% 678
2023
Q2
$202K Buy
+2,000
New +$200K 0.01% 552
2022
Q3
Sell
-2,679
Closed -$226K 591
2022
Q2
$226K Buy
2,679
+110
+4% +$9.65K 0.02% 468
2022
Q1
$225K Sell
2,569
-44
-2% -$3.81K 0.02% 547
2021
Q4
$229K Buy
+2,613
New +$217K 0.02% 554

Other funds holding NVS

Axxcess Wealth Management's NVS Position: Q2 2026 in Review

Axxcess Wealth Management increased its Novartis (NVS) stake by 15% in Q2 2026, buying an estimated $215K and bringing the position to 10,748 shares worth $1.68M. The position accounts for 0.03% of the portfolio, ranked #420.

Axxcess Wealth Management first reported a position in NVS in Q4 2021 and has held it in 16 quarters since. 943 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Axxcess Wealth Management held 10,748 shares of Novartis worth $1.68M as of Q2 2026.
  • Axxcess Wealth Management bought 1,433 Novartis shares in Q2 2026, an estimated $215K.
  • Novartis made up 0.03% of Axxcess Wealth Management's portfolio in Q2 2026, its #420 holding.
  • Axxcess Wealth Management first reported a position in Novartis in Q4 2021 and has held it in 16 quarters since.
  • 943 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Axxcess Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.